Shots:
- Nimbus has entered into a multi-year research collaboration & exclusive, worldwide license agreement with Eli Lilly to develop a novel oral treatment for obesity & other metabolic diseases
- Building on their prior AMPK cardiometabolic collaboration, Nimbus & Lilly have entered into a new partnership applying Nimbus’ computational chemistry & structure-based design to an early-stage small-molecule obesity program addressing an unmet need
- As per the deal, Nimbus will receive $55M in upfront & near-term milestones, plus ~$1.3B in development, commercial, & sales milestones, as well as tiered royalties on global net sales
Ref: Nimbus  |  Image: Nimbus & Eli Lilly | Press Release
Related News: Eli Lilly Reports Topline P-III (ATTAIN-MAINTAIN) Trial Results of Orforglipron for Weight Loss MaintenanceÂ
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
